List of Excipients in Branded Drug HYDROMORPHONE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpecGx LLC	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	0406-3308	ANHYDROUS LACTOSE
SpecGx LLC	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	0406-3308	BUTYLATED HYDROXYTOLUENE
SpecGx LLC	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	0406-3308	CELLULOSE ACETATE
SpecGx LLC	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	0406-3308	FERRIC OXIDE RED

Generic Drugs Containing HYDROMORPHONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	hydromorphone hydrochloride	0054-0264	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	hydromorphone hydrochloride	0054-0264	MAGNESIUM STEARATE
SpecGx LLC	hydromorphone hydrochloride	0406-3243	CELLULOSE, MICROCRYSTALLINE
SpecGx LLC	hydromorphone hydrochloride	0406-3243	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in HYDROMORPHONE HYDROCHLORIDE?

# Of NDCs	Excipient
3	ACETONE
1	AMMONIO METHACRYLATE COPOLYMER TYPE A
13	ANHYDROUS LACTOSE
3	BUTYLATED HYDROXYTOLUENE

Last updated: August 10, 2026

Hydromorphone hydrochloride is a mature Schedule II opioid with limited opportunity in conventional immediate-release tablets and injections. The strongest commercial positions are differentiated excipient systems for abuse-deterrent extended release, ready-to-administer parenteral products, low-volume concentrated injections, pediatric and geriatric oral liquids, and formulations that reduce dosing errors or improve stability. The active ingredient is widely genericized, so value depends on regulatory differentiation, manufacturing reliability, hospital contracts, and defensible formulation or device IP.

Hydromorphone Hydrochloride Excipient Strategy and Commercial Opportunities

What is the commercial position of hydromorphone hydrochloride?

Hydromorphone hydrochloride is the water-soluble hydrochloride salt of hydromorphone, a potent mu-opioid receptor agonist used for severe pain. In the United States, approved dosage forms include immediate-release tablets, oral solution, and injection. Extended-release hydromorphone products have also been approved, although commercial availability has changed over time.

Product segment	Typical dosage form	Principal buyers	Commercial status
Immediate-release oral	Tablets, oral solution	Hospitals, retail pharmacies, hospice	Mature generic market
Parenteral	Vials, ampules, prefilled syringes, cartridges	Hospitals, ambulatory surgery, emergency care	Attractive for supply reliability and ready-to-use products
Extended-release oral	Controlled-release tablets	Chronic severe-pain patients	Higher formulation and abuse-deterrence barriers
Concentrated parenteral	High-strength injection	Palliative care, oncology, intensive care	Niche opportunity with medication-error controls
Pediatric and geriatric	Low-strength oral liquid	Hospitals, specialty pharmacies, hospice	Differentiation through dosing accuracy and excipient safety
Novel delivery	Buccal, sublingual, intranasal, implantable	Specialty pain and palliative-care markets	Regulatory and abuse-liability risk is high

The market is structurally different from that of a protected branded product. Generic hydromorphone products compete primarily on supply continuity, manufacturing cost, contract access, hospital formulary position, and product presentation.

Hydromorphone is much more potent than morphine on a milligram basis. That increases the importance of content uniformity, dose measurement, line-clearing procedures, container design, and excipient compatibility. Small formulation or device changes can have meaningful safety consequences.

What excipients are used in hydromorphone hydrochloride products?

Excipients vary by manufacturer and dosage form. Common immediate-release oral tablets may use lactose or another filler, microcrystalline cellulose, starch-based disintegrants, colloidal silicon dioxide, and magnesium stearate. Oral solutions may contain purified water, buffers, sweeteners, flavoring agents, preservatives, and viscosity modifiers. Injectable products generally use water for injection with pH-adjusting agents and tonicity modifiers.

The approved label, not a generic excipient database, controls the definitive composition of a marketed product. FDA labeling for Dilaudid and related products identifies inactive ingredients by dosage form. [1]

Immediate-release tablets

The formulation objective is rapid and reproducible drug release with low manufacturing cost.

A conventional tablet platform may include:

Formulation function	Candidate excipient classes	Strategic purpose
Dilution and compressibility	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Controls tablet size and mechanical strength
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid release
Lubrication	Magnesium stearate, sodium stearyl fumarate	Improves tooling and ejection
Flow control	Colloidal silicon dioxide	Reduces blend segregation
Taste control	Film coating, polymer coating, ion-exchange resin	Improves acceptability and limits manipulation
Identification	Colorants, opacifiers, imprint-compatible coating	Reduces medication errors

The low dose of hydromorphone in some strengths creates a content-uniformity challenge. Direct compression is commercially attractive but may require robust premixing, ordered blending, or granulation to control segregation.

Excipient selection should also consider lactose intolerance, sugar restrictions, gluten claims, dye sensitivity, and hospital formulary preferences. These attributes can support a differentiated generic label without requiring a new active ingredient.

Oral solutions

Oral liquid products create more formulation latitude than tablets. Hydromorphone hydrochloride is highly water soluble, so solubilization is usually less difficult than taste masking, preservative control, pH management, and dosing accuracy.

Commercially relevant excipient systems include:

• Citrate or phosphate buffers for pH control.
• Sodium chloride or other tonicity agents where appropriate.
• Methylparaben, propylparaben, or alternative preservative systems.
• Sucrose, sorbitol, glycerin, or non-sugar sweeteners.
• Flavor systems designed to mask bitterness without increasing pediatric appeal inappropriately.
• Hydroxyethylcellulose or similar viscosity modifiers to reduce dosing variability.
• Unit-dose cups, oral syringes, or prefilled oral dispensers.

A sugar-free, dye-free, alcohol-free oral solution can target pediatric, geriatric, hospice, and institutional use. The main commercial barrier is not active solubility. It is microbiological robustness, preservative effectiveness, extractables and leachables, and a validated dose-measurement system.

Because hydromorphone is a controlled substance, oral liquids also require packaging and distribution controls that limit diversion and reduce accidental ingestion. Child-resistant, unit-dose, tamper-evident packaging is commercially relevant.

Injectable formulations

Parenteral hydromorphone products require control of sterility, endotoxin, particulate matter, pH, osmolality, container closure integrity, and chemical stability.

The principal excipient opportunity is often not a new chemical excipient. It is a better presentation:

• Ready-to-administer prefilled syringes.
• Standardized concentrations that reduce bedside dilution.
• Unit-dose vials with barcoded labels.
• Low-sorbing polymer containers.
• Dual-chamber or dilution-compatible systems.
• Ready-to-use bags for infusion protocols.
• Packaging that separates high-concentration products from standard strengths.

Concentrated injections can reduce volume for patients requiring fluid restriction, including oncology and palliative-care patients. They also increase the risk of fatal dosing errors. A commercial product must therefore combine concentration with strong labeling, segregated packaging, barcode verification, and clear differentiation from lower-strength presentations.

The formulation must be assessed for adsorption to syringe materials, silicone oil exposure, stopper compatibility, light sensitivity, and stability after dilution into common infusion fluids. These properties can create manufacturing and quality barriers that are more defensible than ordinary tablet excipient changes.

What excipient strategies can create patentable hydromorphone products?

The strongest formulation claims usually connect excipient composition with a measurable performance result. Generic claims directed only to “hydromorphone plus a pharmaceutically acceptable excipient” are unlikely to provide meaningful commercial protection for a mature compound.

Abuse-deterrent extended-release systems

An abuse-deterrent platform may use:

• High-molecular-weight polyethylene oxide.
• Crosslinked polymers.
• Swellable matrices.
• Gelling agents.
• Coatings resistant to alcohol or aqueous extraction.
• Ion-exchange or multiparticulate systems.
• Physical barriers to crushing and rapid release.

The development target is not simply slower dissolution. FDA expects abuse-deterrent products to demonstrate resistance to manipulation and, where applicable, pharmacokinetic effects after manipulation. Abuse-deterrent labeling does not eliminate abuse or overdose risk. [2]

Hydromorphone’s potency makes extraction resistance commercially relevant, but it also raises the development burden. A formulation that releases too much drug after crushing, chewing, or solvent exposure can create a substantial safety problem. A successful product would need robust in vitro manipulation data, pharmacokinetic characterization, human abuse-potential studies where required, and clear labeling.

Taste-masked and low-volume oral liquids

Ion-exchange resins, polymer coatings, cyclodextrins, and lipid-based systems can reduce bitterness. The preferred design depends on whether the product is a true solution, suspension, or multiparticulate dispersion.

Commercial claims may focus on:

• Reduced bitterness.
• Improved dose uniformity.
• Lower dosing volume.
• Preservative-free packaging.
• Extended in-use stability.
• Compatibility with oral syringes.
• Reduced adsorption to dosing devices.

A lower-volume liquid is particularly useful because hydromorphone is administered in very small doses. A formulation that permits accurate measurement at 0.1 mL increments can have practical value, but the dose-delivery system must be validated as part of the product.

Stable ready-to-administer injections

Parenteral products may obtain protection through a combination of formulation and container claims. Potential claim areas include:

• Specific pH ranges.
• Buffer and antioxidant systems.
• Low-extractable container materials.
• Reduced sorption to polymer syringes.
• Stability after dilution.
• Terminal sterilization or aseptic manufacturing processes.
• Prefilled delivery devices.
• High-concentration formulations with defined particulate limits.

Manufacturing-process patents may be more valuable than composition patents when the product solves a reproducible hospital-use problem, such as extended in-use stability or reduced preparation steps.

When does hydromorphone hydrochloride lose exclusivity?

Hydromorphone hydrochloride itself is a mature active pharmaceutical ingredient. Basic compound and early formulation exclusivity have generally expired in the United States and major international markets. FDA-approved immediate-release tablets, oral solutions, and injections are available from multiple generic manufacturers.

The relevant exclusivity questions now concern individual products rather than the molecule:

Exclusivity category	Hydromorphone position
New chemical entity exclusivity	Expired
Basic composition-of-matter protection	Expired or commercially irrelevant
Conventional immediate-release generic entry	Established
Pediatric exclusivity	Product-specific and historical
Extended-release formulation protection	Patent- and product-specific
Abuse-deterrent formulation protection	Depends on approved formulation and listing status
Method-of-use protection	Narrow and dependent on approved labeling
Device or packaging protection	Potentially available for new presentations

FDA’s Orange Book identifies approved drug products and listed patents for eligible NDAs. The current Orange Book, FDA patent listings, and individual ANDA litigation records should control any launch analysis. [3]

What is the Orange Book status of hydromorphone hydrochloride?

Hydromorphone products appear across multiple NDA and ANDA records, depending on dosage form and sponsor. The ordinary generic products are generally approved through the ANDA pathway and are not protected by active new-drug exclusivity.

Orange Book analysis should separate:

1. Immediate-release tablets.
2. Oral solutions.
3. Standard injections.
4. Extended-release tablets.
5. Products with device or abuse-deterrent claims.
6. Discontinued products whose patents may remain listed or whose listing history may still affect litigation.

A discontinued product is not automatically irrelevant. Patent listings, 30-month stays, and litigation history can continue to affect an ANDA applicant even when commercial sales have declined. The regulatory status of a discontinued NDA must be distinguished from withdrawal for safety or effectiveness reasons. FDA’s Discontinued Drug Product List and Orange Book provide the relevant regulatory framework. [3,4]

What patent litigation and Paragraph IV risks affect hydromorphone?

The highest Paragraph IV risk historically has involved extended-release hydromorphone products rather than ordinary immediate-release tablets. An ANDA applicant may challenge listed patents by certifying that the patent is invalid, unenforceable, or will not be infringed.

Product type	Paragraph IV exposure	Main litigation issue
Immediate-release tablet	Usually low	Formulation, labeling, or residual listed patents
Oral solution	Low to moderate	Composition, preservative, or method claims
Injection	Low to moderate	Formulation, container, process, or device claims
Extended-release tablet	Higher	Release profile, matrix technology, abuse deterrence
Prefilled syringe	Product-specific	Device, container, and formulation claims

The main legal risk for a new excipient product is claim overlap with controlled-release patents, device patents, and method-of-use patents. A freedom-to-operate review should assess issued claims, prosecution history, terminal disclaimers, patent-term adjustment, reissue activity, and Orange Book listing status.

A formulation patent is stronger when it claims a narrow and reproducible relationship among excipient ratio, dissolution profile, abuse-resistance metric, and pharmacokinetic outcome. A broad excipient list without performance limitations is easier to design around.

How strong is the hydromorphone patent estate?

The legacy patent estate for conventional hydromorphone products is weak because the active ingredient is old and multiple generic products are approved. The estate can be stronger for complex delivery systems.

Patent category	Relative strength	Commercial assessment
Basic hydromorphone composition	Very low	Expired
Conventional tablet excipients	Low	Limited differentiation
Oral-liquid taste masking	Moderate	Useful if tied to sensory and stability data
Abuse-deterrent extended release	Moderate to high	Stronger technical barrier, higher development cost
Ready-to-administer injection	Moderate	Depends on device and hospital workflow
High-concentration injection	Moderate	Safety and labeling risks constrain design
Manufacturing process	Moderate	Can protect quality and scale-up advantages
Packaging and dispensing device	Moderate	Valuable when integrated with medication safety

The practical value of patent protection depends on reimbursement and procurement. Hospitals may buy an unpatented product if it reduces preparation time, medication errors, waste, or nursing labor. A narrowly patented product can still win contracts when it produces measurable operational savings.

Which excipient opportunities are commercially attractive?

Hospital-ready injectable products

Hospitals face pressure to reduce bedside compounding and medication errors. A ready-to-administer hydromorphone syringe or standardized infusion presentation could compete through workflow and safety rather than molecule-level novelty.

Commercial value increases if the product has:

• Barcode-ready packaging.
• Multiple standard concentrations.
• Stable shelf life.
• Clear differentiation between strengths.
• Compatibility with automated dispensing cabinets.
• Reduced preparation and waste.
• Unit-dose reimbursement or contract support.

Pediatric, geriatric, and hospice liquids

A low-volume, preservative-controlled oral liquid can target settings where tablet splitting and compounded solutions create operational problems. The product should prioritize dosing accuracy, palatability without excessive sweetness, storage stability, and compatibility with oral syringes.

Abuse-deterrent extended release

This is the highest-value technical opportunity but also the most demanding. Development requires clinical justification, abuse-deterrence testing, controlled-substance risk management, and a commercial strategy that supports a premium over generic immediate-release products.

Compounding replacement products

Hospitals and specialty pharmacies often compound oral liquids or dilute injectable products. A commercially approved product that replaces common compounding steps may capture value through reduced labor, lower contamination risk, and standardized dosing.

Global markets

Geographic opportunity is strongest where injectable opioids are used in hospitals and palliative care but reliable ready-to-use presentations are limited. Regulatory requirements differ substantially. European, Canadian, Australian, and emerging-market authorities may impose different controlled-substance, excipient, packaging, and stability requirements.

A global strategy should avoid relying on one excipient package. Preservative restrictions, sugar policies, container standards, and local pharmacopoeial requirements can force country-specific versions.

How does hydromorphone compare with morphine and oxycodone?

Attribute	Hydromorphone	Morphine	Oxycodone
Potency	High	Lower milligram potency	Intermediate
Common hospital use	Severe pain, opioid rotation, palliative care	Broadest institutional use	Mainly oral outpatient use
Injection opportunity	Strong	Strong	More limited
Oral-liquid opportunity	Strong	Strong	Moderate
Abuse-deterrent opportunity	Technically attractive but high risk	Established competitive field	Established competitive field
Generic competition	High	Very high	High
Differentiation path	Concentration, safety, delivery system	Cost and broad availability	Oral formulations and abuse deterrence

Hydromorphone can command a niche position because clinicians use it when morphine is inadequate, poorly tolerated, or unsuitable for renal impairment. That clinical role does not by itself create pricing power. A differentiated product must reduce workflow burden or address a formulation problem.

What regulatory pathway applies to a new hydromorphone formulation?

A conventional generic equivalent generally proceeds through an ANDA if it matches the reference product in active ingredient, dosage form, strength, route, labeling framework, and bioequivalence requirements. A materially different formulation, delivery system, abuse-deterrent product, or new indication may require a 505(b)(2) application.

The regulatory pathway affects excipient strategy:

Development concept	Likely pathway
Conventional tablet equivalent	ANDA
Alternative tablet excipients with equivalent performance	ANDA, subject to product-specific requirements
New oral liquid concentration or presentation	ANDA or 505(b)(2), depending on reference and differences
Novel extended-release system	Often 505(b)(2) or NDA strategy
New abuse-deterrent product	505(b)(2) or NDA-based strategy
New delivery device	Combination-product assessment may apply
New indication	505(b)(2) or supplemental NDA

FDA’s guidance on abuse-deterrent opioids and ANDA bioequivalence should shape development planning. [2,5] Controlled-substance manufacturing, security, quotas, recordkeeping, and distribution requirements apply under the Controlled Substances Act and DEA regulations. [6]

What generic launch scenarios exist for hydromorphone?

Low-cost conventional launch

A sponsor can enter with a standard tablet, oral solution, or injection. The capital requirement is relatively low, but price erosion and supply competition are substantial.

Hospital-safety launch

A sponsor can use the same active ingredient in a ready-to-administer format with standardized strengths, barcode labeling, and container differentiation. This approach may support institutional contracts without relying on patent exclusivity.

Specialty liquid launch

A sponsor can target pediatric, hospice, and geriatric use with accurate low-volume dosing and a differentiated excipient profile. The key commercial risks are limited market size, controlled-substance distribution, and substitution by pharmacy compounding.

Complex-formulation launch

An abuse-deterrent extended-release product could support premium pricing and formulation patents. It requires the highest clinical, regulatory, and manufacturing investment and faces substitution from generic immediate-release products.

Key Takeaways

• Hydromorphone hydrochloride is a mature, highly genericized opioid active ingredient.
• Conventional tablet and injection excipient changes offer limited standalone protection.
• The most credible opportunities are ready-to-administer injections, concentrated parenteral products, accurate oral liquids, and abuse-deterrent extended-release systems.
• Potency increases the value of dose-control packaging, content uniformity, container compatibility, and medication-error prevention.
• Orange Book and Paragraph IV analysis must be performed by dosage form and reference product, not at the molecule level.
• A 505(b)(2) strategy may be appropriate for novel delivery, controlled-release, abuse-deterrent, or device-integrated products.
• Commercial success will depend heavily on hospital procurement, supply reliability, manufacturing scale, and workflow economics.
• Formulation patents are strongest when tied to measurable dissolution, extraction resistance, stability, pharmacokinetic, or dosing-performance results.

FAQs About Hydromorphone Hydrochloride Excipient and Formulation Strategy

Can hydromorphone hydrochloride be formulated without preservatives?

Yes. Preservative-free oral or injectable products are technically possible, but they require suitable packaging, sterility or microbiological controls, stability data, and validated in-use handling. Preservative-free presentations are most commercially relevant for sensitive patient populations and single-dose use.

Is hydromorphone hydrochloride suitable for an abuse-deterrent tablet?

Yes, but potency creates a high safety burden. The product must demonstrate resistance to crushing, chewing, extraction, or other manipulation and must establish appropriate pharmacokinetic and abuse-deterrence performance under FDA requirements.

Which excipients are most useful for hydromorphone taste masking?

Ion-exchange resins, polymer coatings, cyclodextrins, lipid systems, and optimized flavor-sweetener combinations are possible approaches. The best platform depends on whether the product is a solution, suspension, tablet, or multiparticulate dosage form.

Can a hydromorphone prefilled syringe receive patent protection?

Yes. Protection may cover the formulation, syringe materials, concentration, stability period, dose-delivery configuration, container closure, or labeling and safety features. Device and formulation claims should be evaluated together.

Is a hydromorphone oral liquid a significant commercial opportunity?

It is a niche opportunity rather than a mass-market opportunity. The strongest targets are pediatric care, hospice, geriatrics, specialty pharmacies, and institutions that want to reduce compounding, improve low-dose accuracy, or standardize controlled-substance handling.

References

1. U.S. Food and Drug Administration. (n.d.). Dilaudid- hydromorphone hydrochloride injection, solution; Dilaudid- hydromorphone hydrochloride tablet; hydromorphone hydrochloride oral solution prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

4. U.S. Food and Drug Administration. (2024). Discontinued drug product list. FDA.

5. U.S. Food and Drug Administration. (2021). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or animal origin. FDA.

6. Drug Enforcement Administration. (2024). Controlled substances act and DEA regulations. U.S. Department of Justice.